Treatment for Human Papillomavirus

Johns Hopkins University, Baltimore, MD
Human Papillomavirus+2 More Conditions
What conditions do you have?

Study Summary

This trial is testing a new vaccine to see if it is safe and effective in preventing HPV in women.

Eligible Conditions
  • Human Papillomavirus (HPV) Type 16
  • Cervical Intraepithelial Neoplasia Grade 3 (CIN 3)
  • Cervical Intraepithelial Neoplasia Grade 2

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 week

1 week
Number of participants experiencing dose limiting toxicities at each dosing level

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

0 Treatment Group

48 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 1

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 week

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,272 Previous Clinical Trials
41,230,680 Total Patients Enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
539 Previous Clinical Trials
31,017 Total Patients Enrolled
Kimberly Levinson, MDPrincipal InvestigatorJohns Hopkins University

Eligibility Criteria

Age 18+ · Female Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You agree to take antiretroviral medication as prescribed.
You are expected to live for at least 4 more months.

Who else is applying?

What state do they live in?
What site did they apply to?
University of Alabama at Birmingham100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
Why did patients apply to this trial?
  • "I love to help others"
How many prior treatments have patients received?

Frequently Asked Questions

What is the current participant count for this clinical experiment?

"Affirmative. According to, this trial began accepting patients on September 14th 2020 and is still recruiting as of April 13th 2022. 48 individuals are being recruited from two sites for this study." - Anonymous Online Contributor

Unverified Answer

Are researchers accepting new participants for this study at the present time?

"Affirmative. According to, the research was publicised on September 14th 2020 and most recently updated on April 13th 2022. The trial requires 48 participants between 2 sites for enrollment into the study." - Anonymous Online Contributor

Unverified Answer

Has this treatment been validated by the FDA?

"This treatment has a safety rating of 1 due to its Phase 1 status, indicating that the efficacy and safety have yet to be established." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.